Webinars

The CPhI & P-MEC China's Virtual Expo Connect announced its extension last week. The online event will continue to June 30 with valued services and infinite opportunities for both domestic and international clients. Also, multiple fresh scheduled webinars have been published in VEC content program in succession covering various sectors. While in the last week’s Chinese pharma market, the first therapeutic effect data release of Junshi Biosciences and Vigonvita's VV116, a small-molecule oral drug for COVID-19, captivated the industry. According to the study published in the journal Emerging Microbes & Infections, VV116 showed signs of improved performance and effectiveness in treating patients with non-severe Omicron infection.

As the CPhI & P-MEC China VEC event comes to its fourth week, a wave of online Hosted Buyer Video Meeting registrations appears. The dedicated team of the exclusive programme helps qualified buyers arrange video meetings with targeted suppliers based on their purchasing requirements. Return back to the pharma markets, Hengrui Medicine said a global phase III trial of its PD-1 inhibitor camrelizumab and VEGFR inhibitor apatinib, has successfully hit its goals in newly diagnosed patients with liver cancer. The company plans to start a conversation soon with FDA for a potential new drug application.

The Virtual Expo Connect 2022 is in full swing this week. Cameron Bardliving, the director of operations from Jefferson Institute for Bioprocessing, and GlobalData's senior director Peter Shapiro appeared in the VEC webinar and conducted in-depth sharing and discussion focusing on new cell and gene therapies. Looking back on the pharma news of this week, AstraZeneca and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu has been granted Breakthrough Therapy Designation for patients with HER2-low metastatic breast cancer in the US. While in China, its marketing application for the treatment of patients with HER2-positive unresectable or metastatic breast cancer treated with one or more prior anti-HER2-based regimens was proposed to be included in the updated publicity list of priority review.

The Virtual Expo Connect event of CPhI & P-MEC China was fully launched on April 21. Speakers from Bachem guested on the VEC webinar and shared their experience and insight on how to partner with an experienced CDMO to meet peptide and oligonucleotide drug developers’ manufacturing needs. While in the last week’s Chinese pharma market, Ascletis said that in antiviral cellular assays, the antiviral potency of ASC11 was 31-fold of that of Nirmatrelvir, a compound found in Pfizer's Paxlovid. The data suggested that its drug ASC11 showed the potential to be an effective treatment for COVID-19.